3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

  • PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NWHPSZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKzcW0> NGrmdXczcA>? NEX0W2RFVVOR M{XWeZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? MYSyOVcyPjV4MR?=
A549  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3Wm9vO22P MmTZNog> MYjEUXNQ M13UcZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? MnHUNlU4OTZ3NkG=
95D NFjncmZCeG:ydH;zbZMhSXO|YYm= NXXMNFltPW2P M2DucVJp MWnEUXNQ NUnydZpEcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo MUWyOVcyPjV4MR?=
A549  MWHBdI9xfG:|aYOgRZN{[Xl? MoXjOY1O NUfHUY1{Omh? NIrIUFBFVVOR MX7pcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NEPheZQzPTdzNkW2NS=>
NBL-W-S  Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTDbYEydU1? MUK2bC=> NYntcFFC\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> NE\JfpUzPTN{M{KyNi=>
NBL-W-S  Ml7pRZBweHSxc3nzJGF{e2G7 MnX2NY1O M4rFTVZp NFm1RVRqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x NX\yRXhlOjV|MkOyNlI>
A2780cp  NHnEeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxcW0> M{HPc|Fp M{DWWIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MXyyOVMzOjZ7NB?=
A549  NHnLW4xHfW6ldHnvckBCe3OjeR?= M2L1bFVuVQ>? NYnrcllHOmh? M{H4[JN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NHfXblgzPTJ6NU[yPC=>
H157 MnzRSpVv[3Srb36gRZN{[Xl? MWS1cW0> MV2ybC=> Mojxd5VxeHKnc4Pld{BUWENiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhVEN|LVnJ MVuyOVI5PTZ{OB?=
MDR Mnq4RZBweHSxc3nzJGF{e2G7 NGDXfYUyOG2P NWXkdGZvPmh? MXLzeJJmdme2aHXud{B1cGVicH;3[ZIhd2ZiYX70bYNidmOncjDkdpVoew>? M3nrcFI2ODF7N{Cx
HT-29  Mlz1RZBweHSxc3nzJGF{e2G7 NFLvW|UydU1? M1OyOFQ5cA>? NF\1T5FFVVOR M33SS4VvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MmjtNlQ5PDJzNUi=
Microglia  M3S4T2Fxd3C2b4Ppd{BCe3OjeR?= MlvoOY1O NFHae5czPGh? M{DIe4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmTxNlQ5OTh4MEG=
A2780cp M37UfWFxd3C2b4Ppd{BCe3OjeR?= NVvNTm0zOi53bV2= NVfM[WhXOWh? M1fTNYRlUDKR NEjYeodmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MW[yOFgyPzl2Nh?=
HepG2 NWflSZBxTnWwY4Tpc44hSXO|YYm= MXu1cW0> MkniOIg> MlLTbY5kemWjc3XzJGhNKHKnbHXhd4U> NHOzNYszPDdzM{W4Oy=>
A549 NYjU[W5SSXCxcITvd4l{KEG|c3H5 NVHhTWpvPW2P MnPpOFhp NIfO[oxl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL NVLa[nhCOjR5ME[zNFM>
U2OS NIHWZoVCeG:ydH;zbZMhSXO|YYm= MWGxNI1O MmrDNlRp MW\pcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> MmL4NlQ3OzlyMUO=
Saos-2 NGHaNlZCeG:ydH;zbZMhSXO|YYm= MX[xNI1O MUmyOIg> MojSbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 NYDEOldiOjR4M{mwNVM>
A549 M33pNGFxd3C2b4Ppd{BCe3OjeR?= NVi1NWVUOTCvTR?= NYi2R5M{PDiq MUfhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ NH3XNmczPDZ{NkeyNi=>
HCT116  MVLBdI9xfG:|aYOgRZN{[Xl? MkTWOY1O M1jhdVI1cA>? M2HsdIVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= MlvxNlQ3OjZ3MkK=
HGC-27 NYj1XlV{TnWwY4Tpc44hSXO|YYm= NFOzW3gyOG2P M1nsR|Fp MkPubY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= M3HK[VI1PDF4M{S5
U2OS  NGPOZWdHfW6ldHnvckBCe3OjeR?= NYrvZVM1OC53L{HtUS=> MWS0PIg> Ml30bY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NVvzeo05OjR|NUizOFI>
MG-63 M1LiemZ2dmO2aX;uJGF{e2G7 MkXpNE42NzGvTR?= MWe0PIg> NF21[oxqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NYrjcXJyOjR|NUizOFI>
MG-63 Mor4RZBweHSxc3nzJGF{e2G7 NYHaUHFSOC53L{HtUS=> MmHTN|Jp NYXaPFV{\W6qYX7j[ZMhe2GuaX7vcZlkcW5vaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NHnYZ4ozPDN3OEO0Ni=>
MG-63 Mn3YRZBweHSxc3nzJGF{e2G7 NF[4UIUyOG2P MV2xNog> MYrlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NVfXOJMzOjR|NUizNFE>
NTUB1 M3S2eWFxd3C2b4Ppd{BCe3OjeR?= M3zHcFVuVQ>? NEe5bIEyNjWq M1LNZ5BwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? M33BRVI1OzR7MUe2
T24 Ml;oRZBweHSxc3nzJGF{e2G7 M4XYclVuVQ>? NWXMem9IOS53aB?= M3nIfJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NXrpW4lEOjR|NEmxO|Y>
SGC-7901  MVXBdI9xfG:|aYOgRZN{[Xl? NFj0dHgzdU1? NYezdnJvOWh? Mn7ObY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MUSyOFMzOTN2MB?=
SMMC-7721 NUjPeYlbSXCxcITvd4l{KEG|c3H5 M3jaXVJuVQ>? Mne5NYg> MoXmbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? NGjDcWYzPDN{MUO0NC=>
ECSCs  NELkZ4VCeG:ydH;zbZMhSXO|YYm= MVOxNI1O MVG0bC=> M4G1doRm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM> NHLYdFQzPDNzOUGwPS=>
MCF-7  NFzGb5RHfW6ldHnvckBCe3OjeR?= NHHScZcyOG2P NYXxZVkyOjSq MWTpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| M2HPd|I1OzF3NUe4
UOK257 M3z6OWFxd3C2b4Ppd{BCe3OjeR?= NWrrSZpOPW2P MXOzbC=> M1\rbYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? NXGxNmZNOjR|MEW2NFQ>
ACHN-5968 MUjBdI9xfG:|aYOgRZN{[Xl? MXi1cW0> M3TXXVNp MoGw[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? MknzNlQ{ODV4MES=
Huh7 NFfnPJJCeG:ydH;zbZMhSXO|YYm= M2fNcVJuVQ>? NGLvTIoyOmh? NYDWZ5ZDTE2VTx?= MkfRbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NWTZ[IdYOjR{OUezNFA>
Hep3B MUDBdI9xfG:|aYOgRZN{[Xl? NV3WVnprOm2P NVLsR4lvOTKq NX\wdXYzTE2VTx?= NFPlWZRqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MXeyOFI6PzNyMB?=
RKO M3TMT2Z2dmO2aX;uJGF{e2G7 MnrSNo1O NU[yNW9UOWh? MnT3SG1UVw>? M3nUdYVvcGGwY3XzJINmdGxiZHXheIgh[nliZ3Xs[IFv[W27Y3nu NVLvdWl{OjR{OUG3O|c>
HepG2 E47 NHnDRpJHfW6ldHnvckBCe3OjeR?= Mmj0Nk42dU1? Mn\OOFhp NFm4cI5qdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 MUCyOFI4Ozd|OB?=
LoVo  MmPWRZBweHSxc3nzJGF{e2G7 MXm1cW0> MnXzOFhp M2P3fYVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? NUG1VmhsOjR{MEG4NVI>
WiDr M3i5eGZ2dmO2aX;uJGF{e2G7 NI\GZYQyOG2P MnHBNYg> MlPMbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v M1PBXFI1OTlyNEi5
H1299  NVv1U2RiTnWwY4Tpc44hSXO|YYm= MnnjNVBuVQ>? NUPKbHVsPGh? M{XMWIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NIDCT2czPDF5M{KwPC=>
H460 MnG2SpVv[3Srb36gRZN{[Xl? NV;pR4NOOTCvTR?= MWi0bC=> M3S0WIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MX[yOFE4OzJyOB?=
A549 Ml\tSpVv[3Srb36gRZN{[Xl? M3zIOFExdU1? MUC0bC=> NEnaZldqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?= Mn;LNlQyPDJ5M{W=
Hep3B NWXNS3YzSXCxcITvd4l{KEG|c3H5 NULnbnVnPW2P MV6yOIg> NWXrT4Fm[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ MWGyOFA3PjZ7Mx?=
SMMC-7721 NEexVWJCeG:ydH;zbZMhSXO|YYm= NYfa[nRWPW2P NYiwb5VnOjSq MYTheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= MmrMNlQxPjZ4OUO=
HO8910 MonTRZBweHSxc3nzJGF{e2G7 NVLNb5FGOTCvTR?= Ml3wNVJp NEn5ZnFmdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>? M1vsXlI{QTh|NkGw
MCF7 MlL6SpVv[3Srb36gRZN{[Xl? MoDvOY1O Mo\JNlRp MkH5bY5kemWjc3XzJGN2VyCrbnT1Z4VlKGOnbHyg[IVifGh? MlvuNlM6PjJ4Mkm=
HONE-1  MkHQSpVv[3Srb36gRZN{[Xl? MlvBOY1O NInwfYoycA>? Mk\ydoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u NYK5PJIxOjN6OUKzOVg>
HeLa NELleItHfW6ldHnvckBCe3OjeR?= NHjlUngyOG2P M2T5NVJp MX\zeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> MVyyN|g3PDd|OB?=
HepG2 M2njWWZ2dmO2aX;uJGF{e2G7 M3LzW|ExdU1? M1LWOlI1cA>? NWjUbHFQcW6qaXLpeJMhe2mWSVfBVk0h[W6mIFjCV3MucW6mdXPl[EBifXSxcHjh[5k> MmH3NlM5OTdyNEC=
SH-SY5Y MWTGeY5kfGmxbjDBd5NigQ>? MUWxcW0> M1zUZVI1cA>? NYfHV45FcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRQS1B? NXi0VXJwOjN5NEOxOFg>
SH-SY5Y M2WwZmFxd3C2b4Ppd{BCe3OjeR?= MnvsOY1O NF3y[moycA>? NGjySmNi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= NIDl[|QzOzZzOUO5OS=>
PC12  M1e3UWZ2dmO2aX;uJGF{e2G7 NH6w[lQyOG2P NFP5TmkzPGh? NID3bGx4[XSnch?= NYexN5pWyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= MmLpNlM3ODN7N{m=
OV2008 M3XuWWFxd3C2b4Ppd{BCe3OjeR?= M4jFVFVuVQ>? NFfJXmUzPGh? M{Ls[oNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| NWnaVldEOjN3OUKyPFE>
A2780 MUXBdI9xfG:|aYOgRZN{[Xl? NHHWbY02dU1? NUjwXmlYOjSq NGWx[5hkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= MlziNlM2QTJ{OEG=
Saos-2  MU\BdI9xfG:|aYOgRZN{[Xl? MXOxcW0> M4HKflk3cA>? NWjpSZdWcW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> MkHSNlM2PjNzN{G=
1321N1 NXe2TnAzS3m2b4TvfIlkcXS7IFHzd4F6 NVfRSXBnPW2P MUCyOIg> NHTjWlRxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= MkPDNlM2OjV{NkW=
SH-SY5Y NWTwe|NqS3m2b4TvfIlkcXS7IFHzd4F6 MmDNOY1O MknONlRp NEDySmFqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NGfWbHozOzV{NUK2OS=>
HT-29  NVzrRlNXTnWwY4Tpc44hSXO|YYm= NHTGSGMydU1? NXPzXGJrPDhxOU\o MU\pcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NEfSOlYzOzVyOEK3Ni=>
OR6 NYX3fnNwTnWwY4Tpc44hSXO|YYm= Ml36NVBuVQ>? M2qxRVczcA>? NUTnW2Nue3WycILld5NmeyCKQ2[gdoVxdGmlYYTpc44h[W6mIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NIjlRXYzOzN7NUi3OS=>
Hela  M4\lTWZ2dmO2aX;uJGF{e2G7 NFnRTYg2dU1? M1qyc|I1cA>? NG\MWI1qdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NUPjSno{OjN|OUW2O|k>
MCF-7  M2OxWWZ2dmO2aX;uJGF{e2G7 M4GwelVuVQ>? MkHzNlRp M3XsNYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> MoXVNlM{QTV4N{m=
HUVECs NHXqR4NHfW6ldHnvckBCe3OjeR?= MkHmN41O NXmyZm9vOjSq MY\icI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 M2LwS|I{OzV6OUK4
T24 MX7GeY5kfGmxbjDBd5NigQ>? MkOzNVBuVQ>? MnHPNYg> MlnwdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= MX2yN|M2PDB6MB?=
U251MG  NIP2VJJHfW6ldHnvckBCe3OjeR?= M2DpXlNuVQ>? MojpNYg> NXvTdpZUe3WycILld5NmeyCOQ{OtTWkheHKxdHXpckBmgHC{ZYPzbY9v M3nZ[lI{OzN6NkG4
GTL-16  NVHiTZVSSXCxcITvd4l{KEG|c3H5 NUj2O|dzPW2P MVWyOIg> MljLdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO= MYWyN|MyOzR7MB?=
T-47D Mn\BSpVv[3Srb36gRZN{[Xl? NIT4W4EyOG2P MUeybC=> Mn7tbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? NXzOemNwOjN|MECwNlY>
PaCa44 Mk\XRZBweHSxc3nzJGF{e2G7 MkToNk42dU1? MlLDNYg> NI[yfZBz\WS3Y3XzxsBo\W6rcHnuMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NX6zc|NxOjNzMkSxNVI>
MDA-MB231 M1i4fWZ2dmO2aX;uJGF{e2G7 MnjaOY1O MUSxbC=> NVXoU3RxcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? MYeyN|A5QDh3MB?=
HeLa NHrkNG9CeG:ydH;zbZMhSXO|YYm= MUOxNI1O NFn1XYMzcA>? M1Hsc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> MYWyN|AxODF|NR?=
SK-HEP-1 NI\nfllCeG:ydH;zbZMhSXO|YYm= M17hTlExdU1? NFftd40ycA>? M4PxeZBzd3SnY4TzJIFo[Wmwc4SgZZV1d3CqYXf5JIFv\CCrbnT1Z4V{KGGyb4D0c5NqeyCrbjDieYZidGmwLYTy[YF1\WRiY3XscJM> MUCyNlg2QDZ2OR?=
HepG2 NXPjUodnSXCxcITvd4l{KEG|c3H5 NXnBVVB{O22P M3LhblVp MlfndoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> NGPnTVczOjh|NkW5OS=>
MCF-7  MULGeY5kfGmxbjDBd5NigQ>? NIOweY0zdU1? MoLWNlRp NGnrPZpqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg MonTNlQ6PzB4N{[=
MDA-MB-231 NHzEWIxHfW6ldHnvckBCe3OjeR?= MmewNo1O MWGyOIg> Ml\YbY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MlHZNlQ6PzB4N{[=
MCF-7  NHe1dmtHfW6ldHnvckBCe3OjeR?= MlrtNo1O NHLLZos1QGh? MWHwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> NHrWUpIzPDl5ME[3Oi=>
MDA-MB-231 MVXGeY5kfGmxbjDBd5NigQ>? NUjHNVRxOm2P M{DaT|Q5cA>? M1v1VJBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? MV[yOFk4ODZ5Nh?=
PANC-1  M2\zcGFxd3C2b4Ppd{BCe3OjeR?= MnTsNY1O Mn7ZOFhp NHn0UVFFVVOR M{frXoVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ M17FNVI1QDR{MUW4
MDA-MB 231 NVr4coU6SXCxcITvd4l{KEG|c3H5 Mn2yOY1O NHPXXWsxNjWq NHzzNFNud2S3bHH0[ZMhXG:lb33pcuKvyqCrbnT1Z4VlKGGyb4D0c5Nqew>? NXfTfmdJOjR6M{C3PFE>
Microglia  MU\BdI9xfG:|aYOgRZN{[Xl? MV:1cW0> NHvWd2kzPGh? MXnk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= Mlv4NlQ5OTh4MEG=
A2780cp M{jQWmFxd3C2b4Ppd{BCe3OjeR?= MnfaNk42dU1? NHrsUHgycA>? NH;RNnVl\Eh{Tx?= MUTlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo NUHUVXpSOjR6MUe5OFY>
HepG2 M2fEXWZ2dmO2aX;uJGF{e2G7 NUHXRXJZPW2P MX20bC=> MlP1bY5kemWjc3XzJINmdGy3bHHyJIxmfmWuczDv[kBJVMLi NIP0fm8zPDdzM{W4Oy=>
U2OS M1rCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLRe3YyOG2P Mo[yNlRp NVnOOmhucW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 M1LZdVI1PjN7MEGz
HCT116 MYPBdI9xfG:|aYOgRZN{[Xl? M2jue|VuVQ>? NGT2cG0zPGh? NWXxRmZLTE2VTx?= NGfpRmJmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> NEP3RZYzPDZ{NkWyNi=>
MCF-7  MlflRZBweHSxc3nzJGF{e2G7 MYqwMlFuVQ>? MWK2bC=> M{D2T4VvcGGwY3XzJJNqenSrbn;sMYlv\HWlZXSgZZBweHSxc3nz NF3uOZEzOjd3MUm4PS=>
PC-3  M2HrSGFxd3C2b4Ppd{BCe3OjeR?= M1rEVVJuVQ>? M4D1elJp NIP3XXNqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?= M2jHVFIzPzR3NUiw
U251  MmnHRZBweHSxc3nzJGF{e2G7 MYS1cW0> NUHmXWdDOjSq M2PVfYlv[3KnYYPld{BUOS2rbnT1Z4VlKGOnbHyg[IVifGh? MUCyNlU4QTd6OB?=
HeLa  M1rY[2Fxd3C2b4Ppd{BCe3OjeR?= MWe1cW0> NXz2ZlE5OjSq M{LnV4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> M4Oyc|IzPTR3MUK4
A549 NIXMPVRHfW6ldHnvckBCe3OjeR?= MXiwMlFuVQ>? NGHCe3IzPGh? M{W5dpN2eHC{ZYPz[ZMhW1VzMUK3OE1qdmS3Y3XkJINmdGxiZHXheIg> M1vrNFIzPDZ4OU[w
pDCs NV\EZ5lVTnWwY4Tpc44hSXO|YYm= NF64VXkyOG2P NH3UcYsxNjWq NYrxeGI3yqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> MlH0NlI{QTZ3OUm=
BGC-823 NGG0NWdHfW6ldHnvckBCe3OjeR?= MY[1cW0> MmT0Nog> MmPabY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> NFmxemozOjN{MkG1Ni=>
U937 M2TKeWZ2dmO2aX;uJGF{e2G7 MWWycW0> NEf1UWMyOmh? MWnk[YNz\WG|ZYOgeIhmKGG3dH;wbIFogSC{YYTpc:Kh NWnSN5I4OjJzNUWxOVA>
Marc-145 MX7GeY5kfGmxbjDBd5NigQ>? M2HLRlVuVQ>? M33o[|EzNzJ2L{O2bC=> MmS5doVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w NWLlSXN3OjJzMUm5NFA>
HBx  MkPRRZBweHSxc3nzJGF{e2G7 MonNNVBuVQ>? NUS1RmNzPDiq M3TlWWROW09? MojLbY5kemWjc3XzJINmdGxiZHXheIg> M{TyXlIzODJyMEe4
MCF-7 NVzte2xtTnWwY4Tpc44hSXO|YYm= NVz0dpRrOTCvTR?= M2\QWVQ5cA>? NXfOd4ZK[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? NEXKRlUzOTl|MUmzOy=>
RMPI8226  MkPPSpVv[3Srb36gRZN{[Xl? Mo\nOY1O M{[3SFFp M1fDZZN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? NInWUJczOTlzNU[yNC=>
PC12/TetOn M4jPN2Z2dmO2aX;uJGF{e2G7 NID4fnExNjFxMX3N NVPkc4pCOTiq M2LXNYxm[WS|IITvJO6yNXO7bjjXWEkh[WOldX31cIF1cW:wLDD0c5hq[2m2eTygZY5lKG:uaXfvcYVzKG[xcn3heIlwdsLi MVWyNVkxPjZ3OR?=
HeLa  MmrqR5l1d3SxeHnjbZR6KEG|c3H5 NXTxUGkyOm2P NXqz[5Y2OjSq MoLjbY5pcWKrdHXzJJRp\SCleYTveI95cWOrdImgc4Yhe2muaXLpcolvKHSxIFjlUIEh[2WubIOu MkPHNlE5PzV|OEW=
Jurkat MV;GeY5kfGmxbjDBd5NigQ>? NUW2WVgyOTCvTR?= NGT2SGsycA>? NFvoOlVl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M2fDSFIyQDZ2MEO3
K562 MUjGeY5kfGmxbjDBd5NigQ>? NX\aS2VtOTCvTR?= MnO0NYg> NVzOcFZl\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NVvzfI5DOjF6NkSwN|c>
Nara-H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO3OY1O MUO0PIg> NUPNNoJr\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> NWmxRXF{OjF6MEWwN|M>
HUVECs M2Tse2Z2dmO2aX;uJGF{e2G7 NGTvVIcyOG2P MmDzNE42cA>? NFvqN4hl\WO{ZXHz[ZMhfGinIFHHSU1DW0GrbnT1Z4VlKGG3dH;wbIFogSCuZY\l MV6yNVQ3QDV7Mh?=
HepG2 NIniPJZCeG:ydH;zbZMhSXO|YYm= NYX3W4FmOm2P NF:wfWUycA>? MYnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDj[YxtKGSnYYTo NV\pVW1{OjF2NUO2PVE>

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)
In vivo water 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID